Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2016

01.09.2016 | short review

Practice changing information in aggressive lymphoma, ASH 2015

verfasst von: Dr. Michael A. Fridrik

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Out of the numerous papers dealing with lymphoma at the American Society of Hematology (ASH) 2015 meeting, three could change clinical practice. The DA-EPOCH-R regimen has improved the evidence for efficacy in Burkitt lymphoma. For lymphoproliferative disease after solid organ transplantation rituximab is a reasonable first-line treatment and nonresponders can be salvaged with R‑CHOP. For anaplastic large cell lymphoma the addition of etoposide to the CHOP regimen is an option. However, better regimens with new drugs are eagerly awaited.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. CrossRefPubMed Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. CrossRefPubMed
2.
Zurück zum Zitat Fridrik MA. (editor) Burkitt and lymphoblastic lymphoma. Rickmansworth: ESMO Press s/s/media limited; 2012. Fridrik MA. (editor) Burkitt and lymphoblastic lymphoma. Rickmansworth: ESMO Press s/s/media limited; 2012.
3.
Zurück zum Zitat Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25. CrossRefPubMedPubMedCentral Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Offner F, Samoilova O, Osmanov E, Eom H‑S, Topp MS, Raposo J, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–901. CrossRefPubMedPubMedCentral Offner F, Samoilova O, Osmanov E, Eom H‑S, Topp MS, Raposo J, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–901. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, et al. Final results of a randomized phase 2 multicenter study of two Bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d’etude des Lymphomes de l’Adulte (GELA) study FL-05. Blood. 2010;116(21):768. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, et al. Final results of a randomized phase 2 multicenter study of two Bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d’etude des Lymphomes de l’Adulte (GELA) study FL-05. Blood. 2010;116(21):768.
Metadaten
Titel
Practice changing information in aggressive lymphoma, ASH 2015
verfasst von
Dr. Michael A. Fridrik
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0271-7